Alkermes settles with Amneal over opioid dependence treatment
31-07-2019
Indivior appeal fails to stop generic opioid addiction challenge
15-07-2019
Victor Moussa / Shutterstock.com
The US Patent Trial and Appeal Board (PTAB) has instituted an inter partes review (IPR) into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Patent Trial and Appeal Board, Nalox-1 Pharmaceuticals, Opiant Pharmaceuticals, naloxone, Narcan, inter partes review
